I have invited Mr. Koos to host the Ask the Doctor forum in January and he has kindly accepted.
Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
Current focus on COPD and Immuno-Therapeutic Cancer Treatment
San Diego, CA (PRWEB) November 10, 2009 -- Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in development in the areas of immuno-therapeutic treatment of cancer and Chronic Obstructive Pulmonary Disease (COPD) and their potential to generate significant revenue for the Company.
1. Immuno-therapeutic treatment of cancer ? The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. The Company?s initial goal is to treat 2,000 dogs at $3,000 per dog (yielding $6,000,000 in revenue) and believes revenue could begin to be generated within the next 9 months. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.
2. Entest has applied for a contract with the National Cancer Institute (NCI) for the initial development of an immuno-therapeutic cancer drug. This contract, if awarded to Entest, will have a value of $200,000 and will cover Phase I clinical evaluation. If the drug demonstrates reasonable efficacy, NCI may coordinate and fund further development through Phases II and III, with the ultimate goal being commercialization of the drug in partnership with NCI.
3. COPD ?There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. The Company foresees substantial revenue in treating COPD and is currently in discussions with several entities regarding possible joint ventures involving the Company?s developing patent pending treatment.
Entest anticipates funding a significant amount of its research development costs by obtaining grant funding. The Company is in the process of applying for $3 million of federal grant funding for both COPD treatment and immuno-therapeutic treatment of cancer.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
David R. Koos, Chairman & CEO
Entest BioMedical Inc.
www.EntestBio.com
Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
Current focus on COPD and Immuno-Therapeutic Cancer Treatment
San Diego, CA (PRWEB) November 10, 2009 -- Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in development in the areas of immuno-therapeutic treatment of cancer and Chronic Obstructive Pulmonary Disease (COPD) and their potential to generate significant revenue for the Company.
1. Immuno-therapeutic treatment of cancer ? The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. The Company?s initial goal is to treat 2,000 dogs at $3,000 per dog (yielding $6,000,000 in revenue) and believes revenue could begin to be generated within the next 9 months. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.
2. Entest has applied for a contract with the National Cancer Institute (NCI) for the initial development of an immuno-therapeutic cancer drug. This contract, if awarded to Entest, will have a value of $200,000 and will cover Phase I clinical evaluation. If the drug demonstrates reasonable efficacy, NCI may coordinate and fund further development through Phases II and III, with the ultimate goal being commercialization of the drug in partnership with NCI.
3. COPD ?There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. The Company foresees substantial revenue in treating COPD and is currently in discussions with several entities regarding possible joint ventures involving the Company?s developing patent pending treatment.
Entest anticipates funding a significant amount of its research development costs by obtaining grant funding. The Company is in the process of applying for $3 million of federal grant funding for both COPD treatment and immuno-therapeutic treatment of cancer.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
David R. Koos, Chairman & CEO
Entest BioMedical Inc.
www.EntestBio.com